

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	01948/088004
	Serial No.	10/624,809
	Applicant	Karumanchi et al.
	Filing Date	July 21, 2003
	Group	1647
	IDS Filed	October 25, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
/I.D./	2006/0183175	August 17, 2006	Buhimschi et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
/I.D./	WO 2006/069373	June 29, 2006	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
/I.D./	Del-Sorbo et al., "The Synthesis of Platelet-Activating Factor Modulates Chemotaxis of Monocytes Induced by HIV-1 Tat," <i>Eur. J. Immunol.</i> 29:1513-1521 (1999).					
	Gordon et al., "Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients with Advanced Cancer," <i>J. Clin. Oncol.</i> 19:843-850 (2001).					
	Hunter et al., "Serum Levels of Vascular Endothelial Growth Factor in Preeclamptic and Normotensive Pregnancy," <i>Hypertension</i> 36:965-969 (2000).					
	Margolin et al., "Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination with Chemotherapy in Patients with Advanced Cancer: Pharmacologic and Long-Term Safety Data," <i>J. Clin. Oncol.</i> 19:851-856 (2001).					
✓	Sugimoto et al., "Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria," <i>J. Biol. Chem.</i> 278:12605-12608 (2003).					

EXAMINER	/Ian Dang/	DATE CONSIDERED	04/23/2007
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			